A single blind, Randomized, Parallel Group study to compare efficacy and safety of Unani formulation Safoof-e-Dama Haldiwala with Salbutamol in patients with Zeequn Nafas(Bronchial Asthma)

Central Council for Research in Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•(1) Patients of Bronchial Asthama for atleast 6 months having following symptoms: wheeze, Shortness of Breath, Chest Tightness and cough that vary over time and in intensity, Expiratory airflow limitation as suggested by a decreased FEV1.
•(2) Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
•(3) patients with Asthma Control Questionnaire Score >1.5

•The patients of Zeeq-un-Nafas (Bronchial Asthma) with following conditions will be excluded from the study:
•1. Patients below 18 years and above 65 years of age., 2. Pregnant and lactating mother
•3. FEV1/FVC ratio < 50%
•4. Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
•5. Patients with Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years.
•6. Patient with co-morbidities, Diabetes Mellitus, Hepatic, Renal Insufficiency and Heart disease .
•7. Patients with Tobacco Smoking.
•8. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

发起方